American International Group, Inc. Immunovant, Inc. Transaction History

American International Group, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$30.27 - $43.79 $6,931 - $10,027	-229 Reduced 0.85%	26,591 $859,000
Q4 2023 Feb 13, 2024	SELL	$31.31 - $44.19 $3,381 - $4,772	-108 Reduced 0.4%	26,820 $1.13 Million
Q3 2023 Nov 13, 2023	BUY	$18.55 - $39.96 $17,752 - $38,241	957 Added 3.68%	26,928 $1.03 Million
Q2 2023 Aug 04, 2023	BUY	$14.2 - $23.75 $64,141 - $107,278	4,517 Added 21.05%	25,971 $492,000
Q1 2023 May 12, 2023	BUY	$15.27 - $19.72 $6,520 - $8,420	427 Added 2.03%	21,454 $332,000
Q4 2022 Feb 10, 2023	BUY	$6.59 - $17.75 $13,259 - $35,713	2,012 Added 10.58%	21,027 $373,000
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $1,057 - $1,713	269 Added 1.43%	19,015 $106,000
Q2 2022 Aug 12, 2022	SELL	$3.38 - $5.65 $4,735 - $7,915	-1,401 Reduced 6.95%	18,746 $73,000
Q1 2022 May 13, 2022	SELL	$5.06 - $8.77 $5,859 - $10,155	-1,158 Reduced 5.44%	20,147 $111,000
Q4 2021 Feb 11, 2022	SELL	$7.33 - $9.32 $4,669 - $5,936	-637 Reduced 2.9%	21,305 $182,000
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $6,456 - $10,471	921 Added 4.38%	21,942 $191,000
Q2 2021 Aug 13, 2021	SELL	$9.4 - $16.85 $7,820 - $14,019	-832 Reduced 3.81%	21,021 $222,000
Q1 2021 May 07, 2021	BUY	$13.08 - $49.6 $745 - $2,827	57 Added 0.26%	21,853 $351,000
Q4 2020 Feb 12, 2021	BUY	$36.36 - $52.71 $33,451 - $48,493	920 Added 4.41%	21,796 $1.01 Million
Q3 2020 Nov 04, 2020	BUY	$22.61 - $38.9 $207,740 - $357,413	9,188 Added 78.61%	20,876 $735,000
Q2 2020 Aug 12, 2020	BUY	$13.87 - $28.44 $162,112 - $332,406	11,688 New	11,688 $285,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.